Adherence in the treatment of psoriasis: A systematic review

Dermatology

Volumn 222, Issue 4, 2011, Pages 363-374

  Augustin, M ^a   Holland, B ^a,b   Dartsch, D ^b   Langenbruch, A ^a   Radtke, M A ^a,c  

^a Institute for Health Services Research in Dermatology and Nursing   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Medication adherence; Psoriasis outcome; Quality of life; Treatment compliance

Indexed keywords

ANTIPSORIASIS AGENT; CORTISONE; ETRETIN; SALICYLIC ACID;

AGE DISTRIBUTION; ARTICLE; CLINICAL PROTOCOL; DESCRIPTIVE RESEARCH; HUMAN; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PSORIASIS; PSYCHOSOCIAL CARE; QUALITY OF LIFE; SELF REPORT; SEX DIFFERENCE; SYSTEMATIC REVIEW;

CHRONIC DISEASE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; PATIENT SATISFACTION; PSORIASIS; QUALITY OF LIFE;

EID: 80052431557     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000329026     Document Type: Article

References (71)

1. Schaefer I, Rustenbach SJ, Zimmer L, Augustin M: Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 2008; 217: 169-172.
2. Schäfer I, Rustenbach SJ, Radtke M, Augustin J, Glaeske G, Augustin M: Epidemiology of psoriasis in Germany - analysis of secondary health insurance data. Gesundheitswesen 2011; 73: 308-313.
3. Neimann AL, Porter SB, Gelfand JM: Epidemiology of psoriasis. Expert Rev Dermatol 2006; 1: 63-75.
4. Augustin M, Reich K, Reich C, Purwins S, Jeff Rustenbach S, Schäfer I, Radtke M: Quality of psoriasis care in Germany - results of the national study PsoHealth 2007. J Dtsch Dermatol Ges 2008; 6: 640-645.
5. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K: Disease severity, quality of life and health care in plaque-type psoriasis: A multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-372. (Pubitemid 351630108)
6. Blome C, Simianer S, Purwins S, Laass A, Rustenbach SJ, Schaefer I, Radtke M, Augustin M: Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 2010; 221: 154-159.
7. Reich K, Krüger K, Mössner R, Augustin M: Epidemiology and clinical pattern of psoriatic arthritis in Germany: A prospective interdisciplinary epidemiological study of 1,511 patients with plaque-type psoriasis. Br J Dermatol 2009; 160: 1040-1047.
8. Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M: Prevalence and clinical features of psoriatic arthritis and joint complaints in 2,009 patients with psoriasis: Results of a German national survey. J Eur Acad Dermatol Venereol 2009; 23: 683-691.
9. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M: Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-151.
10. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I: Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633-636.
11. Boehncke WH, Sterry W: Psoriasis - A systemic inflammatory disorder: Clinic, pathogenesis and therapeutic perspectives. J Dtsch Dermatol Ges 2009; 7: 948-952.
12. Sohn S, Schöffski O, Prinz J, Reich K, Schubert E, Waldorf K, Augustin M: Cost of moderate to severe plaque psoriasis in Germany: A multicenter cost-of-illness study. Dermatology 2006; 212: 137-144. (Pubitemid 43260729)
13. Berger K, Ehlken B, Kugland B, Augustin M: Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005; 3: 511-518. (Pubitemid 40942633)
14. Schöffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, Reich K: Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: A multicenter study. J Dtsch Dermatol Ges 2007; 5: 209-219.
15. Kimball AB, Guerin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM: Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol 2011; 25: 157-163.
16. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284. (Pubitemid 32240779)
17. Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, Sigurgeirsson B: Quality of life in 6,497 Nordic patients with psoriasis. Br J Dermatol 2002; 146: 1006-1016. (Pubitemid 34779481)
18. Schmid-Ott G, Künsebeck HW, Jäger B, Sittig U, Hofste N, Ott R, Malewski P, Lambrecht F: Significance of the stigmatization experience of psoriasis patients: A 1-year follow- up of the illness and its psychological consequences in men and women. Acta Derm Venereol 2005; 85: 27-32. (Pubitemid 40254676)
19. Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti S, Lotti T, Schäfer G, EUROPSO Patient Survey Group: European patient perspectives on the impact of psoriasis: The EUROPSO Patient Survey. Br J Dermatol 2006; 155: 729-736. (Pubitemid 44352553)
20. Kurd SK, Troxel AB, Crits-Cristoph P, Gelfand JM: The risk of depression, anxiety, and suicidality in patients with psoriasis: A population- based cohort study. Arch Dermatol 2010; 146: 891-895.
21. Augustin M, Reich K, Radtke MA: Lebensqualität, Compliance und Empowerment bei Psoriasis, ed 1. Bremen, Uni-Med, 2007, p 64.
22. World Health Organization: Adherence to long term therapy: Evidence for action. http://www.who.int/chronic-conditions/ adherencereport/en/2003 (accessed January 8, 2009).
23. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005; 353: 487-497. (Pubitemid 41127293)
24. Serup J, Lindblad AK, Maroti M, Kjellgren KI, Niklasson E, Ring L, Ahlner J: To follow or not to follow dermatological treatment - A review of the literature. Acta Derm Venereol 2006; 86: 193-197. (Pubitemid 43875201)
25. Castelo-Branco C, Palacios S, Ferrer-Barriendos J, Alberich X, Cervantes Study Group: Do patients lie? An open interview vs a blind questionnaire on sexuality. J Sex Med 2010; 7: 873-880.
26. Farmer KC: Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999; 21: 1074-1090. (Pubitemid 29326165)
27. Mirosky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74. (Pubitemid 16125389)
28. Horne R, Weinman J: Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999; 47: 555-567. (Pubitemid 30029305)
29. Thompson K, Kulkarni J, Sergejew AA: Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000; 42: 241-247. (Pubitemid 30216535)
30. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB: The concordance of self-report with other measures of medication adherence: A summary of the literature. Med Care 2004; 42: 649-652.
31. Rudd P, Marshall G: Resolving problems of measuring compliance with medication monitors. J Compliance Health Care 1987; 2: 23-35. (Pubitemid 17063009)
32. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, Canning C, Platt R: Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37: 846-857.
33. Guenette L, Moisan J, Preville M, Boyer R: Measures of adherence based on self-report exhibited poor agreement with those based on pharmacy records. J Clin Epidemiol 2005; 58: 924-933. (Pubitemid 41115777)
34. Hodari KT, Nanton JR, Carroll CL, Feldman SR, Balkrishnan R: Adherence in dermatology: A review of the last 20 years. J Dermatolog Treat 2006; 17: 136-142. (Pubitemid 44147829)
35. Balkrishnan R, Carroll CL, Camacho FT, Feldman SR: Electronic monitoring of medication adherence in skin disease: Results of a pilot study. J Am Acad Dermatol 2003; 49: 651-654. (Pubitemid 37210278)
36. Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R: Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: Commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol 2004; 51: 212-216.
37. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE: Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581-583. (Pubitemid 29480408)
38. Brown KK, Rehmus WE, Kimball AB: Determining the relative importance of patient motivations for non-adherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 2006; 55: 607-613. (Pubitemid 44436629)
39. Gokdemir G, Ari S, Koslu A: Adherence to treatment in patients with psoriasis vulgaris: Turkish experience. J Eur Acad Dermatol Venereol 2008; 22: 330-335. (Pubitemid 351247423)
40. Fouéré S, Adjadj L, Pawin H: How patients experience psoriasis: Results from a European survey. J Eur Acad Dermatol Venereol 2005; 19: 2-6. (Pubitemid 41726918)
41. Zaghloul SS, Goodfield MJ: Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004; 140: 408-414. (Pubitemid 38469243)
42. Feldman SR, Camacho FT, Krejci-Manwaring J, Carroll CL, Balkrishnan R: Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007; 57: 81-83. (Pubitemid 46908856)
43. Carroll CL, Feldman SR, Camacho FT, Balkrishnan R: Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol 2004; 151: 895-897. (Pubitemid 39482127)
44. Yentzer BA, Yelverton CB, Pearce DJ, Camacho FT, Makhzoumi Z, Clark A, Boles A, Fleischer AB Jr, Balkrishnan R, Feldman SR: Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis. J Am Acad Dermatol 2008; 59: 577-581.
45. Bhosle MJ, Feldman SR, Camacho FT, Timothy Whitmire J, Nahata MC, Balkrishnan R: Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatolog Treat 2006; 17: 294-301. (Pubitemid 44595018)
46. Storm A, Andersen SE, Benfeldt E, Serup J: One in 3 prescriptions are never redeemed: Primary non-adherence in an outpatient clinic. J Am Acad Dermatol 2008; 59: 27-33.
47. Van De Kerkhof PCM, de Hoop D, de Korte J, Cobelens SA, Kuipers MV: Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000;200:292-298. (Pubitemid 30451575)
48. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR: Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 26: 2-12.
49. Kircik LH, Del Rosso JQ: Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol 2009; 8: 546-559.
50. Fleischer AB, Feldman SR, Rapp SR, Reboussin DM, Exum ML, Clark AR, Rajashekhar V: Disease severity measures in a population of psoriasis patients: The symptoms of psoriasis correlate with self-administered psoriasis area severity index scores. J Invest Dermatol 1996; 107: 26-29. (Pubitemid 26236089)
51. Awadalla FC, Yentzer B, Balkrishnan S, Feldman SR: A role for denial in poor adherence to psoriasis treatment. J Dermatolog Treat 2007; 18: 324-325. (Pubitemid 350223200)
52. Richards HL, Fortune DG, Griffiths CE: Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol 2006; 20: 370-379.
53. Bahmer JA, Petermann F, Kuhl J: Psychosocial factors in psoriasis: A pilot study. Hautarzt 2007; 58: 959-965. (Pubitemid 350096064)
54. Richards HL, Fortune DG, Chong SL, Mason DL, Sweeney SK, Main CJ, Griffiths CE: Divergent beliefs about psoriasis are associated with increased psychological distress. J Invest Dermatol 2004; 123: 49-56. (Pubitemid 38833462)
55. Uhlenhake EE, Kurkowski D, Feldman SR: Conversations on psoriasis - what patients want and what physicians can provide: A qualitative look at patients and physician expectations. J Dermatolog Treat 2010; 21: 6-12.
56. Fortune DG, Richards HL, Kirby B, McElhone K, Main CJ, Griffiths CE: Successful treatment of psoriasis improves psoriasisspecific but not more general aspects of patients' well-being. Br J Dermatol 2004; 151: 1219-1226. (Pubitemid 40030170)
57. Zalewska A, Miniszewska J, Chodkiewicz J, Narbutt J: Acceptance of chronic illness in psoriasis vulgaris patients. J Eur Acad Dermatol Venereol 2007; 21: 235-242. (Pubitemid 46128700)
58. Chu T: Better patient compliance in psoriasis. Practitioner 2000; 244: 238-242.
59. Marinker M, Shaw J: Not to be taken as directed. BMJ 2003; 326: 348-349. (Pubitemid 36241466)
60. Larsen J, Stovring H, Kragstrup J, Hansen DG: Can differences in medical drug compliance between European countries be explained by social factors: Analyses based on data from the European Social Survey, round 2. BMC Public Health 2009; 9: 145.
61. Koehler AM, Maibach HI: Electronic monitoring in medication adherence measurement: Implications for dermatology. Am J Clin Dermatol 2001; 2: 7-12.
62. Renzi C, Picardi A, Abeni D, Agostini E, Baliva G, Pasquini P, Puddu P, Braga M: Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 2002; 138: 337-342. (Pubitemid 34226331)
63. Renzi C, Abeni D, Picardi A, Agostini E, Melchi CF, Pasquini P, Puddu P, Braga M: Factors associated with patient satisfaction with care among dermatological outpatients. Br J Dermatol 2001; 145: 617-623.
64. Kinney MA, Feldman SR: What's new in the management of psoriasis? G Ital Dermatol Venereol 2009; 144: 103-117.
65. Laine C, Davidoff F, Lewis CE, Nelson EC, Nelson E, Kessler RC, Delbanco TL: Important elements of outpatient care: A comparison of patients' and physicians' opinions. Ann Intern Med 1996; 125: 640-645. (Pubitemid 126450599)
66. Young SD, Oppenheimer DM: Different methods of presenting risk information and their influence on medication compliance intentions: Results of three studies. Clin Ther 2006; 28: 129-139. (Pubitemid 43254997)
67. Fortune DG, Richards HL, Griffiths CE, Main CJ: Targeting cognitive-behaviour therapy to patients' implicit model of psoriasis: Results from a patient preference controlled trial. Br J Clin Psychol 2004; 43: 65-82. (Pubitemid 38379783)
68. Bonnekoh B, Schmid-Ott, Herold S, Sayegh- Jodehl S, Dierkes J, Gollnick H: Interdisciplinary training program for adults with psoriasis: Six months follow-up. Hautarzt 2006; 57: 917-922. (Pubitemid 44526294)
69. Werfel T, Breitbart E, Kleinheinz A, Gieler U, Schmid-Ott G: The educational program for the management of psoriasis vulgaris according to the rules of the Task Force on Dermatological Prevention: Current status. Hautarzt 2006; 57: 913-916. (Pubitemid 44526293)
70. Rapp SR, Feldman SR, Exum L, Fleischer AB, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407. (Pubitemid 29418506)
71. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR: New treatments for psoriasis: Which biologic is best? J Dermatolog Treat 2006; 17: 96-107.